Keywords: IBS, Irritable bowel syndrome, Market forecasts, Pipeline, GlobalData

Pushing the IBS pipeline for promising therapies

Article | 27 August 2012

Both the current filed status and Phase III pipeline for irritable bowel syndrome (IBS) are sparse. The recent marketed products ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in